Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 1963 of 5804
-
Hospital alcohol therapy boosts recovery engagement
Disease control OngoingThis study is a 3-arm randomized clinical trial to evaluate the effectiveness of hospital-initiated Alcohol Use Disorder treatment, involving a Brief Negotiated Interview (with referral and telephone booster) alone, BNI+facilitated provision of MAUD, BNI+facilitated provision of …
Phase: NA • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New scan could spot lung cancer in the brain more clearly
Diagnosis Recruiting nowThis study investigates fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) as a Positron Emission (PET) imaging agent in Non-Small Cell Lung Cancer (NSCLC) patients with brain metastases. Investigators hypothesize that \[18F\]-αvβ6-BP PET/Computed Tomography (CT) is a sensitive tool fo…
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
New cholesterol drug inclisiran tested in everyday patients
Disease control OngoingThis observational prospective study aims to evaluate the LDL-C change and adherence to inclisiran in combination with other lipid lowering therapies or lipid lowering treatments (LLTs) under conditions of routine clinical practice.
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New depression pill shows promise in early trial
Symptom relief CompletedThis is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Di…
Phase: PHASE2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Timing matters: study tests best moment to remove dead tissue in pancreatitis
Disease control CompletedAcute pancreatitis is one of the most common diagnoses made in gastroenterology wards worldwide which causes a great deal of pain and expense along with fatal complications. Approximately, 10-20% of patients progress to necrotizing pancreatitis that result in significant morbidit…
Phase: NA • Sponsor: University of Tehran • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could less radiation be enough for head and neck cancer?
Disease control Recruiting nowThe purpose of this study is to test the treatment approach of de-escalated radiation and chemotherapy followed by a planned neck dissection surgery in people with head and neck cancer. The study will look at how effective the treatment approach is against participants' cancer.
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Could a buddy system for HIV care improve lives?
Disease control Recruiting nowThe overall goal of this study is to test whether dyadic and focused case management will (1) improve financial wellbeing, (2) improve access to food, (3) increase linkage and retention rates for individuals living with HIV or those taking PrEP (PrEP persistence), and (4) increas…
Phase: NA • Sponsor: University of Chicago • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug for rare blood cancer studied in everyday practice
Disease control Recruiting nowPolycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution. The results of several randomised trials for the treatment with new cytoreductive agents are now available, among which a new ropegyla…
Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New hope for hard-to-treat breast cancer? early trial combines two targeted drugs
Disease control CompletedA phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.
Phase: PHASE1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New HIV vaccine candidate enters early safety testing
⭐️ VACCINE ⭐️ CompletedThis study will evaluate the safety and tolerability (including reactogenicity) of candidate vaccine A244/B.63521 with Army Liposome Formulation (ALF) mixed with the saponin QS-21(Quillaja saponaria-21) (ALFQ) adjuvant. The purpose of this phase I randomized, double-blind clinica…
Phase: PHASE1 • Sponsor: U.S. Army Medical Research and Development Command • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo aims to shrink pancreatic tumors before surgery
Disease control OngoingThis study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the neoadjuvant setting.
Phase: PHASE1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 26, 2026 13:51 UTC
-
Heart pump patients get new hope from diabetes drug
Disease control CompletedThe main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Phase: PHASE4 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
SpikoGen booster shows promise in small COVID-19 study
Disease control CompletedThe purpose of the study is to assess the effectiveness of Spikogen vaccine when used as a 3rd or 4th dose booster in adults who have been previously vaccinated with any Covid-19 vaccine types, including mRNA vaccine, adenoviral vector vaccines, recombinant protein vaccines, or i…
Phase: PHASE3 • Sponsor: Vaxine Pty Ltd • Aim: Disease control
Last updated Jun 26, 2026 18:22 UTC
-
Implantable heart attack alert device tested in Real-World patients
Disease control Recruiting now500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care. Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.
Sponsor: Angel Medical Systems • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Daily ECMO check: could a simple protocol save lives and money?
Knowledge-focused CompletedDecannulation from venovenous extracorporeal membrane oxygenation (VV-ECMO) at the earliest and safest time would be expected to improve outcomes and reduce cost. Daily assessments for readiness to liberate from therapies have demonstrated success in other realms of critical care…
Phase: NA • Sponsor: Vanderbilt University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Digital coaching may help smokers with mental illness stay quit after hospital discharge
Disease control CompletedAll patients with serious mental illness are abstinent while in the hospital for a psychiatric admission yet almost all return to smoking after discharge. The investigators propose to test a digital intervention adapted to the needs of SMI smokers and to being introduced in the i…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New wearable device could ease leg swelling without bulky pumps
Symptom relief CompletedTo evaluate the Koya wearable device - a Novel Portable Non-Pneumatic Active Compression Device (NPCD) in contrast to an advanced pneumatic compression device (APCD)
Phase: NA • Sponsor: Koya Medical, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:03 UTC
-
New hope for lung fibrosis patients: inhaled drug tested for long-term safety
Disease control ENROLLING_BY_INVITATIONStudy RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
5,000 patients to help unlock secrets of kidney disease and transplant outcomes
Knowledge-focused Recruiting nowManaging patients with renal failure requires an understanding of the molecular mechanisms that lead to its occurrence (i.e. upstream of the disease), its worsening and its persistence (i.e. downstream), while also specifying the risk of worsening renal failure (risk stratificati…
Sponsor: University Hospital, Toulouse • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Brain zaps without zaps: neurofeedback shows promise for borderline personality disorder
Symptom relief CompletedThe goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as an intervention for borderline personality disorder.
Phase: NA • Sponsor: Kymberly Young • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC